Tafinlar (Dabrafenib Mesylate) Patent Expiration, LOE Window & CMS Spending
Tafinlar (Dabrafenib Mesylate) by Novartis: FDA Orange Book core substance LOE 2031-04-15 (last listed 2034-02-28), 0 AB generics, $220.2M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N202806 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-04-15 |
| Last Listed Patent or Exclusivity Date | 2034-02-28 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $220.2M |
| 2024 Medicare Part D Spend | $173.9M |
| 2024 Medicaid Spend | $46.3M |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 26.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.